Key Points
- General Counsel Shannon Kelley sold 692 shares at an average price of $497.36 on Jan. 20 for $344,173, and now directly owns 8,481 shares—a 7.54% reduction valued at roughly $4.22 million.
- Madrigal reported a large earnings miss (EPS of ($5.08) vs. consensus ($2.01)), with a negative net margin (~39%) and negative ROE (~41.5%), and analysts forecast -23.47 EPS for the current fiscal year.
- Analyst sentiment is broadly favorable: MarketBeat shows a Moderate Buy consensus and an average target price of $632.64, with individual targets running as high as $745 and several firms rating the stock Buy/Outperform.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) General Counsel Shannon Kelley sold 692 shares of Madrigal Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $497.36, for a total transaction of $344,173.12. Following the transaction, the general counsel directly owned 8,481 shares of the company's stock, valued at approximately $4,218,110.16. This trade represents a 7.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Madrigal Pharmaceuticals Trading Up 0.7%
NASDAQ:MDGL opened at $504.95 on Wednesday. The firm has a market capitalization of $11.47 billion, a P/E ratio of -38.81, a PEG ratio of 4.87 and a beta of -1.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00. The company's 50-day simple moving average is $561.10 and its 200 day simple moving average is $456.18.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts' consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. As a group, analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Several large investors have recently bought and sold shares of MDGL. Toth Financial Advisory Corp purchased a new position in Madrigal Pharmaceuticals in the 4th quarter worth about $1,165,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $375,000. Eastern Bank grew its stake in shares of Madrigal Pharmaceuticals by 32.3% in the fourth quarter. Eastern Bank now owns 86 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 21 shares during the period. Peak Financial Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals by 287.0% during the fourth quarter. Peak Financial Advisors LLC now owns 4,466 shares of the biopharmaceutical company's stock valued at $2,601,000 after purchasing an additional 3,312 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Madrigal Pharmaceuticals by 23.0% during the fourth quarter. SG Americas Securities LLC now owns 6,386 shares of the biopharmaceutical company's stock valued at $3,719,000 after purchasing an additional 1,195 shares during the period. 98.50% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on MDGL shares. Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Cantor Fitzgerald raised Madrigal Pharmaceuticals from a "neutral" rating to an "overweight" rating in a research report on Tuesday, November 4th. Oppenheimer upped their price target on shares of Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the stock an "outperform" rating in a research note on Thursday, November 20th. Citizens Jmp increased their price objective on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a "market outperform" rating in a research report on Tuesday. Finally, Zacks Research lowered shares of Madrigal Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Madrigal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $632.64.
View Our Latest Stock Report on MDGL
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
